The ALS Association

ALS Ice Bucket Challenge Progress
  Contact:
Brian Frederick
The ALS Association
(202) 464-8612
bfrederick@alsa-national.org

 

FOR IMMEDIATE RELEASE

ITF Pharma Launches Partnership with The ALS Association

Washington, D.C. (April 3, 2019) — ITF Pharma, a U.S.-based specialty pharmaceutical company committed to investing in and commercializing impactful medicines in therapeutic areas with unfulfilled needs, has united with The ALS Association to fight to defeat ALS.

ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. Eventually, people with ALS lose the ability to initiate and control muscle movement, which often leads to total paralysis and death within five years of diagnosis. For unknown reasons, veterans are twice as likely to develop ALS as the general population. There is no cure.

“ITF Pharma is proud to partner with The ALS Association in this concerted effort to further the association’s tireless efforts of supporting people living with ALS, their caregivers, health care professionals and the rest of the national ALS community,” said Peter Cook, chief operating officer, ITF Pharma. “ITF Pharma’s mission is to provide valuable therapeutic options and support programs that make a positive difference in the lives of people, and by way of this partnership, we are staying true to our primary focus – the people impacted by ALS. Our team is excited about this initiative with ALSA, and we welcome the opportunity to be a true resource and partner for the ALS community in the United States.”

Through its partnership, ITF Pharma will support national events such as the 2019 National Advocacy Conference, where hundreds of ALS Advocates come to Washington, D.C., to learn about the latest ALS research, network, and visit Capitol Hill to share their stories with members of Congress and gain legislative victories. ITF Pharma is helping people living with ALS and their caregivers from across the country travel to share their stories and let members of Congress know why the time to act is now. In addition, ITF Pharma will support educational webinars on topics critical to the ALS Community.

"We are pleased to partner with ITF Pharma and to leverage the momentum we have seen in the fight against ALS. Collaborations like this are key to rising to the challenge of fighting ALS," said Calaneet Balas, president and CEO of The ALS Association.

About ALS
ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. Over the course of the disease, people lose the ability to move, to speak, and eventually, to breathe. On average, it takes about a year before a final ALS diagnosis is made. The disease is always fatal, usually within five years of diagnosis. There is no cure.

About ITF Pharma
ITF Pharma is a Pennsylvania-based, specialty pharmaceutical company committed to investing in and commercializing impactful medicines in therapeutic areas with unfulfilled needs. ITF Pharma is the U.S. subsidiary of Italfarmaco, a privately held European specialty pharmaceutical company engaged in the development of new and groundbreaking therapies. ITF’s commercial portfolio includes TIGLUTIK™ (riluzole) oral suspension, the first and only thickened liquid formulation of riluzole, approved for the treatment of amyotrophic lateral sclerosis (ALS) by the U.S. Food and Drug Administration in September of 2018.

About The ALS Association
The ALS Association is the largest private funder of ALS research in the world. The Association funds global research collaborations, provides assistance for people with ALS and their families through our nationwide network of chapters and certified clinical care centers, and advocates for better public policies for people with ALS. The ALS Association builds hope and enhances quality of life while urgently searching for new treatments and a cure. For more information about The ALS Association, visit our website at www.alsa.org.

Powered by Blackbaud
nonprofit software